Zhejiang Xinguang Pharmaceutical Co Ltd Market Cap ($332.23 Million)
Market Cap & Net Worth: Zhejiang Xinguang Pharmaceutical Co Ltd (300519)
Zhejiang Xinguang Pharmaceutical Co Ltd market cap. Zhejiang Xinguang Pharmaceutical Co Ltd (SHE:300519) has a market capitalization of $332.23 Million (CN¥2.27 Billion) as of November 4, 2026. Listed on the SHE stock exchange, this China-based company holds position #14015 globally and #4136 in its home market, demonstrating a -8.39% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Zhejiang Xinguang Pharmaceutical Co Ltd's stock price CN¥14.19 by its total outstanding shares 160000000 (160.00 Million). Also see Zhejiang Xinguang Pharmaceutical Co Ltd cash flow conversion for how efficiently the company converts equity into cash flow.
Zhejiang Xinguang Pharmaceutical Co Ltd Market Cap History (2016–2026)
Zhejiang Xinguang Pharmaceutical Co Ltd market cap history from 2016 to 2026. Data shows growth from $776.57 Million to $332.23 Million (6.77% CAGR). Check latest Zhejiang Xinguang Pharmaceutical Co Ltd stock price today for real-time trading data and today's change.
Zhejiang Xinguang Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Zhejiang Xinguang Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore 300519 net assets growth trend to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
1.16x
Zhejiang Xinguang Pharmaceutical Co Ltd's market cap is 1.16 times its annual revenue
Latest Price to Earnings (P/E) Ratio
6.17x
Zhejiang Xinguang Pharmaceutical Co Ltd's market cap is 6.17 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $776.57 Million | $315.31 Million | $118.96 Million | 2.46x | 6.53x |
| 2017 | $381.74 Million | $310.87 Million | $106.16 Million | 1.23x | 3.60x |
| 2018 | $269.62 Million | $276.26 Million | $88.00 Million | 0.98x | 3.06x |
| 2019 | $269.66 Million | $291.26 Million | $93.90 Million | 0.93x | 2.87x |
| 2020 | $328.79 Million | $283.08 Million | $98.98 Million | 1.16x | 3.32x |
| 2021 | $428.87 Million | $320.88 Million | $114.28 Million | 1.34x | 3.75x |
| 2022 | $344.84 Million | $351.49 Million | $108.82 Million | 0.98x | 3.17x |
| 2023 | $375.67 Million | $270.40 Million | $64.36 Million | 1.39x | 5.84x |
| 2024 | $310.69 Million | $267.66 Million | $50.39 Million | 1.16x | 6.17x |
Competitor Companies of 300519 by Market Capitalization
Companies near Zhejiang Xinguang Pharmaceutical Co Ltd in the global market cap rankings as of November 4, 2026. Also see how large is Zhejiang Xinguang Pharmaceutical Co Ltd's balance sheet for a full breakdown of the balance sheet.
Key companies related to Zhejiang Xinguang Pharmaceutical Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #509 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #534 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #580 globally with a market cap of $46.03 Billion USD ( CN¥314.55 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #618 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #509 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #534 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $45.90 |
| #580 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $46.03 Billion | CN¥49.31 |
| #618 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.50 |
Market Capitalization of Zhejiang Xinguang Pharmaceutical Co Ltd (2016–2026)
Market capitalization of Zhejiang Xinguang Pharmaceutical Co Ltd from 2016 to today. Between 2016 and today, Zhejiang Xinguang Pharmaceutical Co Ltd's market cap moved from $776.57 Million to $ 332.23 Million, with a yearly change of 6.77%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥332.23 Million | -4.77% |
| 2025 | CN¥348.85 Million | +12.28% |
| 2024 | CN¥310.69 Million | -17.30% |
| 2023 | CN¥375.67 Million | +8.94% |
| 2022 | CN¥344.84 Million | -19.59% |
| 2021 | CN¥428.87 Million | +30.44% |
| 2020 | CN¥328.79 Million | +21.93% |
| 2019 | CN¥269.66 Million | +0.01% |
| 2018 | CN¥269.62 Million | -29.37% |
| 2017 | CN¥381.74 Million | -50.84% |
| 2016 | CN¥776.57 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Zhejiang Xinguang Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $332.23 Million USD |
| MoneyControl | $332.23 Million USD |
| MarketWatch | $332.23 Million USD |
| marketcap.company | $332.23 Million USD |
| Reuters | $332.23 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Zhejiang Xinguang Pharmaceutical Co Ltd
Zhejiang Xinguang Pharmaceutical Co., Ltd. engages in the research and development, production, and sales of Chinese patent medicines, chemical medicines, and health food in China. It offers pharmaceutical products that cover respiratory, digestive, and urinary systems, as well as cardiovascular, cerebrovascular, trauma, and pediatric diseases. The company was incorporated in 1998 and is headquar… Read more